Abstract 108P
Background
About 70% of patients with colorectal cancer develop liver metastases (LM). Although colorectal cancer patients with resectable LM have a good prognosis, there is little data at the difference in the locations of LM. We investigated how the location of LM affects prognosis of colorectal cancer patients.
Methods
The medical records of 196 colorectal cancer patients with liver metastasis from January 2008 to December 2018 were analyzed retrospectively. We defined liver metastasis within a 3-cm-radius sphere centered on the bifurcation of portal vein by computed tomography as central LM (group C), and other LM outside the 3-cm-radius sphere as peripheral LM (group P). We investigated the relation between location of LM and prognosis by using the Kaplan-Meier method and log-rank test, and the relation between location of LM and resection by using the chi-square test.
Results
Patient characteristics were as follows: median age 68.4 (range 30-87), female/male 115/81, colon/rectal cancer 117/79, advanced/recurrent 150/46, respectively. The characteristics of liver metastasis were as follows: mean maximum tumor size 38 mm (3 - 200), tumor number single/multi 58/138, group C/P 84/112, respectively. Median overall survival (OS) was 31 months [95% confidence interval (CI), 25.5 to 36.5 months] from the date of first diagnosis of LM. We divided 196 patients into two groups ofgroup C (n = 84) and group P (n = 112) by location of LM. Resection rate of LM was 11.9% (group C) and 50.9% (group P). Median OS in group C and group P was 18 months (95% CI, 12.3 to 23.7 months) and 38 months (95% CI, 35.2 to 40.8 months), respectively (p < 0.001). Resection of LM was performed significantly more often in group P than in group C (p < 0.001). Furthermore, the patients with resectable LM had a good prognosis not only in group P (mean OS 135 months, 95% CI, 109.4 to 160.7 months) but also in group C (mean OS 82 months, 95% CI, 67.5 to 96.0 months).
Conclusions
It is suggested that the colorectal cancer patients with peripheral LM might have a better prognosis than the patients with central LM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract
426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy
Presenter: Nobumichi Takeuchi
Session: Poster display session
Resources:
Abstract